HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Steripod Bolt-on Deal Extends Perrigo Into Toothbrush and Razor Accessories

Executive Summary

Perrigo's Ranir division purchased the brand, which includes a portfolio of antibacterial toothbrush protectors, children’s products and tongue cleaners, for an undisclosed amount from Bonfit America.

You may also be interested in...



Ranir Oral Care Deal Could Brighten Perrigo's Turnaround Chances

Ranir has a portfolio of more than 300 oral care solutions including power toothbrushes and heads, whitening strips, manual toothbrushes, floss, dentures and travel kits that it provides to retailers and other distributors in more than 50 countries. Adding Ranir, says Perrigo CEO Murray Kessler, "illustrates a key component of our new strategy, accelerating growth by pursuing adjacent self-care categories."

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

FDA Gets Message In Congress' First Cannabis Policy Hearing: Deliver CBD Regulation

During first-ever congressional hearing on federal policies for lawful use of cannabis, House Energy and Commerce Health Subcommittee Chairwoman Anna Eschoo says with $2m appropriated to develop a regulation on CBD’s use in non-drug products during, FDA should deliver.

Topics

Related Companies

UsernamePublicRestriction

Register

RS149573

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel